JP2024515169A5 - - Google Patents

Info

Publication number
JP2024515169A5
JP2024515169A5 JP2023562501A JP2023562501A JP2024515169A5 JP 2024515169 A5 JP2024515169 A5 JP 2024515169A5 JP 2023562501 A JP2023562501 A JP 2023562501A JP 2023562501 A JP2023562501 A JP 2023562501A JP 2024515169 A5 JP2024515169 A5 JP 2024515169A5
Authority
JP
Japan
Prior art keywords
cells
natural killer
population
combination
killer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2023562501A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515169A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/023660 external-priority patent/WO2022216815A1/en
Publication of JP2024515169A publication Critical patent/JP2024515169A/ja
Publication of JP2024515169A5 publication Critical patent/JP2024515169A5/ja
Withdrawn legal-status Critical Current

Links

JP2023562501A 2021-04-08 2022-04-06 Nk細胞およびcd20標的抗体を用いた癌治療 Withdrawn JP2024515169A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163172401P 2021-04-08 2021-04-08
US63/172,401 2021-04-08
US202163290349P 2021-12-16 2021-12-16
US63/290,349 2021-12-16
PCT/US2022/023660 WO2022216815A1 (en) 2021-04-08 2022-04-06 Treatment of cancer with nk cells and a cd20 targeted antibody

Publications (2)

Publication Number Publication Date
JP2024515169A JP2024515169A (ja) 2024-04-05
JP2024515169A5 true JP2024515169A5 (cg-RX-API-DMAC7.html) 2025-04-14

Family

ID=83546502

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562501A Withdrawn JP2024515169A (ja) 2021-04-08 2022-04-06 Nk細胞およびcd20標的抗体を用いた癌治療

Country Status (6)

Country Link
US (1) US20240180962A1 (cg-RX-API-DMAC7.html)
EP (1) EP4319769A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024515169A (cg-RX-API-DMAC7.html)
KR (1) KR20240024046A (cg-RX-API-DMAC7.html)
AU (1) AU2022254978A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022216815A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018124766A2 (ko) 2016-12-28 2018-07-05 주식회사 녹십자랩셀 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포
EP3633029A4 (en) 2017-05-26 2021-06-09 Green Cross Lab Cell Corporation METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL
KR102774451B1 (ko) 2017-11-14 2025-02-28 앱클론(주) 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
JP7179986B2 (ja) 2018-11-14 2022-11-29 グリーン クロス ラボ セル コーポレーション 形質転換されたt細胞を用いた臍帯血由来のナチュラルキラー細胞の培養方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2717895A1 (en) 2011-06-08 2014-04-16 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
CN104245726A (zh) 2012-03-29 2014-12-24 奥瑞基尼探索技术有限公司 来自人pd1的bc环的免疫调节环状化合物
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
MX2016002544A (es) 2013-09-04 2016-06-17 Squibb Bristol Myers Co Compuestos utiles como inmunomoduladores.
MX2016002970A (es) 2013-09-06 2016-10-07 Aurigene Discovery Tech Ltd Compuestos peptidomimeticos ciclicos como inmunomoduladores.
TR201811077T4 (tr) 2013-09-06 2018-08-27 Aurigene Discovery Tech Ltd İmmünomodülatörler olarak 1,3,4-oksadiazol ve 1,3,4-tiyadiyazol türevleri.
RS57508B1 (sr) 2013-09-06 2018-10-31 Aurigene Discovery Tech Ltd 1,2,4-derivati oksadiazola kao imunomodulatori
WO2015036927A1 (en) 2013-09-10 2015-03-19 Aurigene Discovery Technologies Limited Immunomodulating peptidomimetic derivatives
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
MA40132B1 (fr) 2014-09-11 2019-04-30 Bristol Myers Squibb Co Inhibiteurs macrocycliques des interactions protéine/protéine pd-1/pd-l1 et cd80(b7-1)/pd-li
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
SG11201706901TA (en) 2015-03-10 2017-09-28 Aurigene Discovery Tech Ltd Therapeutic cyclic compounds as immunomodulators
JP2018507885A (ja) 2015-03-10 2018-03-22 オーリジーン ディスカバリー テクノロジーズ リミテッドAurigene Discovery Technologies Limited 免疫調節剤としての1,3,4−オキサジアゾールおよびチアジアゾール化合物
EA201791621A1 (ru) 2015-03-10 2018-02-28 Ауриджен Дискавери Текнолоджис Лимитед 3-замещенные-1,2,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов
WO2016142894A1 (en) 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited 3-substituted 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
KR102894264B1 (ko) 2015-03-10 2025-12-02 오리진 온콜로지 리미티드 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
PL3280729T3 (pl) 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
KR102349677B1 (ko) 2015-05-28 2022-01-12 카이트 파마 인코포레이티드 T 세포 요법을 위해 환자를 컨디셔닝하는 방법
US10745382B2 (en) 2015-10-15 2020-08-18 Bristol-Myers Squibb Company Compounds useful as immunomodulators
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2916874T3 (es) 2015-12-17 2022-07-06 Incyte Corp Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
CA3009474A1 (en) 2015-12-22 2017-06-29 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3190103A1 (en) 2016-01-08 2017-07-12 Rijksuniversiteit Groningen Inhibitors of the pd-1/pd-l1 protein/protein interaction
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US10882833B2 (en) 2016-05-23 2021-01-05 Institute Of Materia Medica, Chinese Academy Of Medical Sciences Phenylate derivative, preparation method therefor, and pharmaceutical composition and uses thereof
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
EP3474845B1 (en) 2016-06-27 2024-03-20 ChemoCentryx, Inc. Immunomodulator compounds
KR20210010678A (ko) 2016-06-30 2021-01-27 난트 홀딩스 아이피, 엘엘씨 난트 암 백신
AU2017294231B2 (en) 2016-07-05 2021-09-09 Guangzhou Maxinovel Pharmaceuticals Co., Ltd Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
CN109689640B (zh) 2016-07-08 2022-01-04 百时美施贵宝公司 可用作免疫调节剂的化合物
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
WO2018026971A1 (en) 2016-08-03 2018-02-08 Arising International, Llc Symmetric or semi-symmetric compounds useful as immunomodulators
WO2018027135A1 (en) * 2016-08-04 2018-02-08 Unum Therapeutics Inc. Treatment of lymphoma using antibody-coupled t cell receptor
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
US10144706B2 (en) 2016-09-01 2018-12-04 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2018045142A1 (en) 2016-09-02 2018-03-08 Polaris Pharmaceuticals, Inc. Immune checkpoint inhibitors, compositions and methods thereof
WO2018051254A1 (en) 2016-09-14 2018-03-22 Aurigene Discovery Technologies Limited Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators
WO2018051255A1 (en) 2016-09-14 2018-03-22 Aurigene Discovery Technologies Limited Cyclic substituted-1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
WO2018124766A2 (ko) 2016-12-28 2018-07-05 주식회사 녹십자랩셀 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포
EP3633029A4 (en) 2017-05-26 2021-06-09 Green Cross Lab Cell Corporation METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL
WO2019008154A1 (en) 2017-07-07 2019-01-10 Rijksuniversiteit Groningen 3- (AZOLYLMETHOXY) BIPHENYL DERIVATIVES AS INHIBITORS OF PROTEIN / PROTEIN INTERACTION PD-1 / PD-L1
WO2019008152A1 (en) 2017-07-07 2019-01-10 Rijksuniversiteit Groningen 3-CYANOTHIOPHENE DERIVATIVES AS INHIBITORS OF PROTEIN / PROTEIN INTERACTION PD-1 / PD-L1
US10919852B2 (en) 2017-07-28 2021-02-16 Chemocentryx, Inc. Immunomodulator compounds
EP3697500A1 (en) 2017-10-18 2020-08-26 Kite Pharma, Inc. Methods of administering chimeric antigen receptor immunotherapy
CN111971059A (zh) 2018-01-31 2020-11-20 细胞基因公司 使用过继细胞疗法和检查点抑制剂的组合疗法
CN112839666A (zh) 2018-05-14 2021-05-25 因达普塔治疗公司 具有增强的抗体导向免疫应答的人自然杀伤细胞亚群
WO2020101361A1 (ko) 2018-11-14 2020-05-22 주식회사 녹십자랩셀 형질전환된 t세포를 이용한 제대혈 유래 자연살해세포의 배양방법
EP4262830A4 (en) 2020-12-17 2025-01-15 Artiva Biotherapeutics, Inc. TREATING CANCER WITH NK CELLS AND AN ANTIBODY DIRECTED TO CD20

Similar Documents

Publication Publication Date Title
Finck et al. Engineered cellular immunotherapies in cancer and beyond
JP2024513958A5 (cg-RX-API-DMAC7.html)
JP2024513522A5 (cg-RX-API-DMAC7.html)
US6544787B1 (en) Non-myeloablative/lymphoablative conditioning regimen to induce patient anti-donor unresponsiveness in stem cell transplantation
ES2224122T3 (es) Inmunoterapia de cancer con linfocitos alogenicos.
CN102271702B (zh) 抗第三方中枢记忆性t细胞、产生其的方法及其在移植和疾病治疗中的用途
Maeda et al. Critical role of host γδ T cells in experimental acute graft-versus-host disease
Mehta et al. Graft-versus-myeloma
CN103282047B (zh) 抗第三方中枢记忆性t细胞在抗白血病/淋巴瘤治疗中的用途
JP2024513514A5 (cg-RX-API-DMAC7.html)
Nanjappa et al. Intrinsic MyD88-Akt1-mTOR signaling coordinates disparate Tc17 and Tc1 responses during vaccine immunity against fungal pneumonia
CN115137752A (zh) 用于干细胞移植的方法
Buckley B-cell function in severe combined immunodeficiency after stem cell or gene therapy: a review
JP2024516619A5 (cg-RX-API-DMAC7.html)
JP2022023136A5 (cg-RX-API-DMAC7.html)
Li et al. Artificial antigen-presenting cells: the booster for the obtaining of functional adoptive cells
JP2023134693A (ja) 人体抹消血液のNK細胞より高い水準のNCR、細胞毒性及びIFN-γ生産能力を有するメモリ様NK細胞の製造方法
Su et al. Coculturing dendritic cells with zoledronate acid efficiently enhance the anti-tumor effects of cytokine-induced killer cells
JP3541950B2 (ja) 癌およびウイルス性疾患を治療するための改変化tall−104細胞の使用
Ishida et al. Generation of Anti‐tumour Effector T Cells from Naïve T Cells by Stimulation with Dendritic/tumour Fusion Cells
Saavedra Immunomodulatory Impact Of Memory T Lymphocytes In Periodontitis
de Paula Immunomodulatory Impact of Memory T Lymphocytes in Periodontitis
Marinkovic et al. Selective inflammation of the tumor microenvironment and invigorated T cell-mediated tumor control upon induced systemic inactivation of TREX1
Herberman Therapy of cancer with interleukin-2-activated natural killer cells
Humphrey 1. Role of Natural Killer (NK) Cells in Resistance